How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Antibodies against human CEACAM1

Organization name

PROvendis GmbH



CEACAM1 is a member of the carcinoembryonic antigen related cell adhesion molecule (CEACAM)-family. The transmembrane glycoprotein is expressed on leukocytes, epithelium and endothelium cells. CEACAM1 plays a central role in the formation of new blood and lymphatic vessels, in the regulation of cell growth, tumor suppression, metastasis formation of tumor cells as well as in immunomodulation. CEACAMs are structurally closely related: they feature the function triggering N-domain and a C-domain consisting of A- and B-domains. Due to the structural similarity it is very challenging to obtain antibodies against specific CEACAM1-domains. CEACAM1 has been detected at elevated levels in the surrounding tissue of tumors and the tumors themselves. It appears that CEACAM1 is a suitable biomarker for the diagnosis and staging of tumors.


The present invention relates to an antibody that exhibit a high affinity and mono-specificity for the A1/B-domains of human CEACAM1. Thus, it is suitable to detect the membrane anchored, the cleaved soluble CEACAM1 and most of its derivatives.

It is of use in several research applications, including ELISA, WB, IP, IHC, fluorescence microscopy and flow cytometry. In addition, the monoclonal antibody (mAB) is suitable for use as a diagnostic tool for the detection of inflammatory disorders (e.g. sepsis, multiple sclerosis) as well as for solid tumors, and applies for therapy monitoring of the latter.

Current Status  

Cancer patient data have been generated that support the diagnostic potential.
A German patent application has been filed. On behalf of the University of Duisburg-Essen, PROvendis offers access to the antibody for commercial use.

Relevant Publication

Singer BB (2005): CEACAM1. UCSD-Nature Molecule Pages (doi:10 1038/mp a003597 01)

Muturi HT et al. (2013): Tumor and Endothelial Cell-Derived Microvesicles Carry Distinct CEACAMs and Influence T-Cell Behavior. PLoS One (doi: 10.1371/journal.pone.0074654)

Klaile E et al. (2013): Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferons. Respiratory Research (doi: 10.1186/1465-9921-14-85)

Competitive Advantages

  • Monoclonal antibody directed against the A1/B-domains of human CEACAM1
  • High affinity and mono-specificity
  • Detect membrane anchored and soluble human CEACAM1 and most of its derivatives
  • Suitable for numerous applications:
    • in cancer research
    • in diagnosis
    • in therapy monitoring
    • as immunmodulator in the
    • therapy of tumors, infections and inflammations

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries